Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

LYL273 for Patients With Relapsed or Refractory mCRC

This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.

Participants needed: 155
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lyell Immunopharma, Inc.Updated: Jun 9, 2026Locations: 4
Eligibility criteria

Adults > 18 years old [+6]

Participants with tumor lesion(s) in a location that may cause perforation of an... [+5]

Read more
Status: Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Participants needed: 400
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Lyell Immunopharma, Inc.Updated: Jun 8, 2026Locations: 38
Eligibility criteria

CAR T cell naïve and eligible to receive a CD19 CART-cell therapy [+11]

Patients ineligible to receive CD19 CAR T-cell therapy [+5]

Read more
Status: Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Participants needed: 270
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lyell Immunopharma, Inc.Updated: May 28, 2026Locations: 34
Eligibility criteria

Age 18 years or older [+9]

History of malignancy other than non-melanoma skin cancer or carcinoma in situ u... [+10]

Read more